HighGravityDataCurrent guidance
15 items
Exact Sciences
Guidance from Exact Sciences’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Nov 3, 2025
Data checked
Feb 13, 2026
What changed in the Nov 3, 2025 release
Each item compared with the same item in the previous release (Nov 3, 2025). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Revenue midpoint increase | for FY2025 | — | “$78 million” | Filing ↗ |
| Raised | Total revenue | for FY2025 | “$3.130 - $3.170 billion” | “$3.220 - $3.235 billion” | Filing ↗ |
| Raised | Total revenue Y/Y growth rate | for FY2025 | “14%” | “17%” | Filing ↗ |
| Raised | Adjusted EBITDA | for FY2025 | “$455 - $475 million” | “$470 - $480 million” | Filing ↗ |
| New | Adjusted EBITDA midpoint increase | for FY2025 | — | “$10 million” | Filing ↗ |
| Raised | Adjusted EBITDA Y/Y growth rate | for FY2025 | “44%” | “47%” | Filing ↗ |
| Raised | Precision Oncology | for FY2025 | “$680 - $695 million” | “$710 - $715 million” | Filing ↗ |
| New | Precision Oncology Y/Y growth rate | for FY2025 | — | “9%” | Filing ↗ |
| Raised | Screening | for FY2025 | “$2.390 - $2.425 billion” | “$2.510 - $2.520 billion” | Filing ↗ |
| New | Screening Y/Y growth rate | for FY2025 | — | “20%” | Filing ↗ |
Show 6 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Precision Oncology revenue | for FY2025 | “$690 - $700 million” | — | Filing ↗ |
| Not restated | Precision Oncology revenue Y/Y growth rate | for FY2025 | “6%” | — | Filing ↗ |
| Not restated | Screening revenue | for FY2025 | “$2.440 - $2.470 billion” | — | Filing ↗ |
| Not restated | Screening revenue Y/Y growth rate | for FY2025 | “17%” | — | Filing ↗ |
| Not restated | Precision Oncology | No period stated | “$690 - $700 million” | — | Filing ↗ |
| Not restated | Screening | No period stated | “$2.440 - $2.470 billion” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Precision Oncology revenue | “$690 - $700 million” | for FY2025 | GAAP-tied | Aug 6, 2025 | 1 | Filing ↗ |
| Precision Oncology revenue Y/Y growth rate | “6%” | for FY2025 | GAAP-tied | Aug 6, 2025 | 1 | Filing ↗ |
| Revenue midpoint increase | “$78 million” | for FY2025 | GAAP-tied | Nov 3, 2025 | 1 | Filing ↗ |
| Screening revenue | “$2.440 - $2.470 billion” | for FY2025 | GAAP-tied | Aug 6, 2025 | 1 | Filing ↗ |
| Screening revenue Y/Y growth rate | “17%” | for FY2025 | GAAP-tied | Aug 6, 2025 | 1 | Filing ↗ |
| Total revenue | “$3.220 - $3.235 billion” | for FY2025 | GAAP-tied | May 1, 2025 | 3 | Filing ↗ |
| Total revenue Y/Y growth rate | “17%” | for FY2025 | GAAP-tied | Aug 6, 2025 | 2 | Filing ↗ |
| Adjusted EBITDA | “$470 - $480 million” | for FY2025 | Company-defined | May 1, 2025 | 3 | Filing ↗ |
| Adjusted EBITDA midpoint increase | “$10 million” | for FY2025 | Company-defined | Nov 3, 2025 | 1 | Filing ↗ |
| Adjusted EBITDA Y/Y growth rate | “47%” | for FY2025 | Company-defined | Aug 6, 2025 | 2 | Filing ↗ |
| Precision Oncology | “$710 - $715 million” | for FY2025 | Company-defined | May 1, 2025 | 2 | Filing ↗ |
| Precision Oncology Y/Y growth rate | “9%” | for FY2025 | Company-defined | Nov 3, 2025 | 1 | Filing ↗ |
| Screening | “$2.510 - $2.520 billion” | for FY2025 | Company-defined | May 1, 2025 | 2 | Filing ↗ |
| Screening Y/Y growth rate | “20%” | for FY2025 | Company-defined | Nov 3, 2025 | 1 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Multi-year productivity plan annual savings target | “$150 million in annual savings by 2026” | for the long term | Company-defined | Aug 6, 2025 | 1 | Filing ↗ |
How one item moved
Total revenue, for FY2025 — every statement across the year, each linked to its filing.
How your Biopharma sector group guides
12 companies in Biopharma. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| BioMarin Pharmaceutical | Aug 6, 2026 | 19 changes |
| Halozyme Therapeutics | Aug 6, 2026 | 6 changes |
| Eli Lilly | Aug 5, 2026 | 5 changes |
| Amgen | Aug 4, 2026 | 5 changes |
| Gilead Sciences | Aug 4, 2026 | 15 changes |
| Moderna | Jul 31, 2026 | 8 changes |
| Neurocrine Biosciences | Jul 30, 2026 | 16 changes |
| Regeneron Pharmaceuticals | Jul 30, 2026 | 22 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2025 | FY2024 | Long-term | No period |
|---|---|---|---|---|
| Precision Oncology revenue | 1 statement | 1 statement | — | — |
| Precision Oncology revenue Y/Y growth rate | 1 statement | — | — | — |
| Revenue | — | 2 statements | — | — |
| Revenue midpoint increase | 1 statement | — | — | — |
| Screening revenue | 1 statement | 1 statement | — | — |
The full record for Exact Sciences and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Feb 13, 2026 | FY2025 Q4 | 0001124140-26-000010 | 0 | Open filing ↗ |
| Nov 3, 2025 | FY2025 Q3 | 0001124140-25-000090 | 10 | Open filing ↗ |
| Aug 6, 2025 | FY2025 Q2 | 0001124140-25-000081 | 11 | Open filing ↗ |
| May 1, 2025 | FY2025 Q1 | 0001124140-25-000042 | 4 | Open filing ↗ |
| Jan 12, 2025 | FY2024 Q4 | 0001124140-25-000008 | 1 | Open filing ↗ |
| Nov 5, 2024 | FY2024 Q3 | 0001124140-24-000081 | 4 | Open filing ↗ |
| Jul 31, 2024 | FY2024 Q2 | 0001124140-24-000067 | 5 | Open filing ↗ |
| May 8, 2024 | FY2024 Q1 | 0001124140-24-000045 | 4 | Open filing ↗ |
Not located in filing
2 values were detected in these releases but could not be matched to an exact sentence in the filing body, so they are not shown as guidance. We surface the count rather than drop it silently.
Show the 2 unmatched spans
| Span | Why | Filed |
|---|---|---|
| revenue = $713 million | span gate: value not verbatim in filing | Nov 5, 2024 |
| Adjusted EBITDA = $335 - $355 million | span gate: value not verbatim in filing | May 8, 2024 |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error